- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
- Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
- Addex Completes $4.2 Million Equity Financing
SmartText not available for this item.
1.45Jun 28 20191.49Jun 25 2019
Markit short selling activity
|Market cap||12.06m CHF|
|EPS (TTM)||-0.5532 |
Data delayed at least 15 minutes, as of Jun 28 2019 14:58 BST.